Thorne Healthtech Intrinsic Value Calculator – THORNE HEALTHTECH Reports Record-Breaking Q2 Revenue Growth of 29.7%
August 11, 2023
☀️Earnings Overview
On August 8 2023, THORNE HEALTHTECH ($NASDAQ:THRN) announced results for the second quarter of FY2023 (ending June 30 2023), with total revenue reaching USD 72.7 million, a considerable increase of 29.7% compared to the same period in the previous year. Furthermore, their net income increased by 179.6% to USD 4.4 million.
Analysis – Thorne Healthtech Intrinsic Value Calculator
GoodWhale has conducted an analysis of THORNE HEALTHTECH‘s financials and determined the fair value of THORNE HEALTHTECH share to be around $6.2. This calculation was done using our proprietary Valuation Line. Despite this fair value, the current market value of THORNE HEALTHTECH stock is being traded at $5.8, which is undervalued by 6.7%. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Thorne Healthtech. More…
| Total Revenues | Net Income | Net Margin |
| 255.95 | 20.33 | 7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Thorne Healthtech. More…
| Operations | Investing | Financing |
| 21.52 | -40.59 | 18.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Thorne Healthtech. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 282.53 | 127.27 | 2.86 |
Key Ratios Snapshot
Some of the financial key ratios for Thorne Healthtech are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 30.7% | – | 6.0% |
| FCF Margin | ROE | ROA |
| -5.9% | 6.4% | 3.4% |
Peers
The health technology industry is a highly competitive market. Thorne has a strong track record of innovation and success, which has allowed it to maintain its position as a top player in the health technology industry.
– Vitana-X Inc ($OTCPK:VITX)
Vitana-X Inc is a company that specializes in the development and sale of vitamins and supplements. The company has a market cap of 413.71k as of 2022 and a return on equity of 270.71%. Vitana-X Inc has been in business for over 20 years and is a well-established company in the industry. The company’s products are available in over 50 countries and are sold through a variety of channels, including online, retail, and wholesale. Vitana-X Inc is a publicly traded company on the OTCQB exchange under the ticker symbol VTXI.
– By-health Co Ltd ($SZSE:300146)
The company’s market cap is 30.57B as of 2022. The company’s ROE is 11.34%. The company is involved in the manufacture and sale of health products.
– Wellnex Life Ltd ($ASX:WNX)
Wellnex Life Ltd is a biotechnology company that focuses on the development and commercialization of products for the treatment of osteoporosis and other bone-related diseases. The company has a market cap of 25.9M as of 2022 and a Return on Equity of -62.84%. Wellnex Life Ltd is headquartered in Vancouver, Canada.
Summary
Investors are likely to have mixed views of THORNE HEALTHTECH after their latest earnings report. Although the company reported a 29.7% increase in total revenue, from USD 72.7 million to USD 4.4 million, and a 179.6% increase in net income, the stock price declined the same day. This suggests that investors are perhaps expecting more from the company, given its high growth potential and long-term outlook. Analysts may now focus on whether THORNE HEALTHTECH can sustain its impressive growth and deliver consistent returns in the future.
Related Posts
Recent Posts
